<DOC>
	<DOCNO>NCT00415961</DOCNO>
	<brief_summary>This trial aim demonstrate non-inferiority CI-CMS-005 Coronary Stent System study device well TAXUS™ Express2™ Drug-Eluting Coronary Stent System in-segment late lumen loss 9 month treatment single de novo lesion per vessel .</brief_summary>
	<brief_title>Multi-Center Clinical Trial : Evaluation Effectiveness Safety</brief_title>
	<detailed_description>This complementary , multi-center , open-label , single-arm trial investigate angiographic clinical patient outcomes Japan . Historical data 2-arm randomized COSTAR II trial use comparison .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>General Inclusion Criteria Eligible percutaneous coronary intervention ( PCI ) Documented stable unstable angina pectoris ( Class I , II , III IV ) , document ischemia , document silent ischemia Documented LVEF ≥25 % within last 6 week . Eligible coronary artery bypass graft surgery ( CABG ) General Known sensitivity paclitaxel polymeric matrix . Planned treatment PCI device target vessel ( ) . MI within 72 hour prior index procedure Patient cardiogenic shock Cerebrovascular Accident ( CVA ) within past 6 month Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150 µmol/L ) Contraindication ASA ticlopidine Thrombocytopenia Active GI bleeding within past three month Known allergy cobalt chromium Any prior true anaphylactic reaction contrast agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>Drug-eluting stent ( DES )</keyword>
</DOC>